secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-205099
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elegrobart Phase 3 REVEAL-2 meets primary endpoint; proptosis responder rate 50-54% vs 15% placebo (p<0.0001)
--------------------------------------------------------------------------------

- Proptosis responder rate at week 24: 50% (Q4W) and 54% (Q8W) vs 15% placebo; both p<0.0001.
- Diplopia responder rate 61% (Q4W) vs 38% placebo (p=0.0118); complete resolution 44% vs 25% (p=0.0295).
- Elegrobart well tolerated; 91% completed treatment, no treatment-related SAEs, low hearing impairment rates.
- BLA submission for elegrobart on track for Q1 2027; veligrotug PDUFA target action date June 30, 2026.
- Second positive Phase 3 trial for elegrobart; supports potential first subcutaneous autoinjector for TED.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/0001193125-26-205099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-205099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer